DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below 50-Day Moving Average of $0.89

Market Beat
2024.09.03 08:15
portai
I'm PortAI, I can summarize articles.

DBV Technologies (NASDAQ:DBVT) stock has crossed below its 50-day moving average, trading as low as {{.Question}}.85. Analysts have assigned a "hold" rating and set various price objectives, with JMP Securities boosting their target. For Q2, DBV reported a loss of ({{.Question}}.34) EPS, missing estimates, with revenues of .16 million. Institutional ownership stands at 71.74%. DBV is a clinical-stage biopharmaceutical company focused on immunotherapy products, including Viaskin for peanut allergies. Analysts predict DBV will report -1.43 EPS for the fiscal year.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.89 and traded as low as $0.85. DBV Technologies shares last traded at $0.90, with a volume of 2,500 shares changing hands.

Get DBV Technologies alerts:

Analyst Ratings Changes

A number of equities research analysts have weighed in on DBVT shares. StockNews.com assumed coverage on shares of DBV Technologies in a report on Tuesday. They set a "hold" rating on the stock. JMP Securities boosted their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a "market outperform" rating in a research note on Wednesday, July 31st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of DBV Technologies in a report on Thursday, August 1st.

Get Our Latest Stock Analysis on DBV Technologies

DBV Technologies Stock Performance

The firm's fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.19. The stock has a market cap of $86.85 million, a P/E ratio of -1.07 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period last year, the business posted ($0.26) earnings per share. Analysts predict that DBV Technologies S.A. will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,986 shares of the company's stock, valued at approximately $49,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Featured Articles

  • Five stocks we like better than DBV Technologies
  • What Are Dividend Contenders? Investing in Dividend Contenders
  • Autodesk Stock: Analysts' Top AI Pick You Shouldn’t Overlook
  • 3 Must-Buy Warren Buffett Stocks for Volatile Times
  • Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
  • There Are Different Types of Stock To Invest In
  • Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ I’m giving you the name of this investment for free (From Porter & Company) (Ad)

Should you invest $1,000 in DBV Technologies right now?

Before you consider DBV Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.

While DBV Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.